Note: Ingredients listed on restricted chemical lists
EC/CAS
25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
>=3-<=7
General Information
Version
5.2
Revision date
2026-05-09
Product name
Proligestone Formulation
1.2.1 Relevant identified uses
Pharmaceutical
supplier name
Merck & Co., Inc
Emergency telephone
1-908-423-6000
Icons in SDS
Company Information
company name
Merck & Co., Inc
e-mail address of the competent person responsible for the Safety Data Sheet
EHSDATASTEWARD@merck.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H351, H360D, H373
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
SECTION 2: Hazards identification
Other hazards
None known
Signal word
Danger
Hazard statements
H351 Suspected of causing cancer. H360D May damage the unborn child. H373 May cause damage to organs (Adrenal gland, Ovary, Uterus (including cervix)) through prolonged or repeated expo- sure.
Prevention
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapors. P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response
P308 + P313 IF exposed or concerned: Get medical attention.
Storage
P405 Store locked up.
Disposal
P501 Dispose of contents and container to an approved waste disposal plant.
2.1 Classification of the substance or mixture
1910.1200) Hazards for the product as supplied Carcinogenicity : Category 2 Reproductive toxicity : Category 1B Specific target organ toxicity : Category 2 (Adrenal gland, Ovary, Uterus (including cervix)) - repeated exposure Other hazards
